Clinical Trial Update: Kinetics of B Cell Response in Infants Menjugate Vaccination [Phase 4]

View source ↗

Summary

A Phase 4 study reports on the kinetics of B cell response in infants receiving the Menjugate meningococcal conjugate vaccine for prevention of meningococcal di…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Disease

Drugs mentioned

• Menjugate (Meningococcal group C conjugate vaccine)

Snippet

Sponsor: Novartis | Conditions: Prevention of Meningococcal Infection | Phase 4 | Status: COMPLETED